CA2300478A1 - Inhibiteurs selectifs du facteur xa - Google Patents

Inhibiteurs selectifs du facteur xa Download PDF

Info

Publication number
CA2300478A1
CA2300478A1 CA002300478A CA2300478A CA2300478A1 CA 2300478 A1 CA2300478 A1 CA 2300478A1 CA 002300478 A CA002300478 A CA 002300478A CA 2300478 A CA2300478 A CA 2300478A CA 2300478 A1 CA2300478 A1 CA 2300478A1
Authority
CA
Canada
Prior art keywords
group
6alkyl
compound
aryl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300478A
Other languages
English (en)
Inventor
Robert M. Scarborough
Bing-Yan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2300478A1 publication Critical patent/CA2300478A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés, leurs sels et des compositions les contenant, actifs contre le facteur Xa des mammifères. Ces composés, de formule (I), sont utiles in vitro et in vivo pour prévenir ou traiter les troubles de la coagulation.
CA002300478A 1997-08-11 1998-08-11 Inhibiteurs selectifs du facteur xa Abandoned CA2300478A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90802997A 1997-08-11 1997-08-11
US8418597P 1997-08-11 1997-08-11
US60/084,185 1997-08-11
US08/908,029 1997-08-11
PCT/US1998/016720 WO1999007732A1 (fr) 1997-08-11 1998-08-11 INHIBITEURS SELECTIFS DU FACTEUR Xa

Publications (1)

Publication Number Publication Date
CA2300478A1 true CA2300478A1 (fr) 1999-02-18

Family

ID=26770692

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300478A Abandoned CA2300478A1 (fr) 1997-08-11 1998-08-11 Inhibiteurs selectifs du facteur xa

Country Status (5)

Country Link
EP (1) EP0994892A1 (fr)
JP (1) JP2001512742A (fr)
CA (1) CA2300478A1 (fr)
NZ (1) NZ502877A (fr)
WO (1) WO1999007732A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU747531B2 (en) 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US6204268B1 (en) 1997-04-14 2001-03-20 Cor Therapeutics, Inc Selective factor Xa inhibitors
NZ500352A (en) 1997-04-14 2001-10-26 Cor Therapeutics Inc Cyclic diaza selective factor Xa inhibitors
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
EP1156803A4 (fr) 1999-02-09 2004-03-17 Bristol Myers Squibb Co Inhibiteurs lactame de fxa et methode
DE60006407T2 (de) 1999-09-13 2004-09-09 3-Dimensional Pharmaceuticals, Inc. Azazykloalkanone serin-protease-hemmer
WO2001079261A1 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Derives de tetrahydro-azepinone servant d'inhibiteurs de la thrombine
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2022261159A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035311A1 (fr) * 1994-06-17 1995-12-28 Corvas International, Inc. Derives de l'acide 3-amino-2-oxo-1-piperidineacetique
WO1996019491A1 (fr) * 1994-12-22 1996-06-27 Biochem Pharma Inc. Peptides de cetoarginine heterocycliques utilises comme inhibiteurs de thrombine
WO1998016523A2 (fr) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Inhibiteurs competitifs du facteur xa

Also Published As

Publication number Publication date
JP2001512742A (ja) 2001-08-28
WO1999007732A1 (fr) 1999-02-18
NZ502877A (en) 2001-11-30
EP0994892A1 (fr) 2000-04-26

Similar Documents

Publication Publication Date Title
CA2300478A1 (fr) Inhibiteurs selectifs du facteur xa
WO1998016547A1 (fr) INHIBITEURS SELECTIFS DU FACTEUR Xa
EP0937073A2 (fr) Inhibiteurs competitifs du facteur xa
US6204268B1 (en) Selective factor Xa inhibitors
US6262047B1 (en) Selective factor Xa inhibitors
CA2268264A1 (fr) Inhibiteurs selectifs du facteur xa
EP0994893B1 (fr) INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE STRUCTURE D'AZEPINONE CONDENSEE
US6369063B1 (en) Selective factor Xa inhibitors
CA2285705A1 (fr) Inhibiteurs selectifs du facteur xa
US6525076B1 (en) Selective factor Xa inhibitors
US6333321B1 (en) Selective factor Xa inhibitors
US6369080B2 (en) Selective factor Xa inhibitors
US6194435B1 (en) Lactams as selective factor Xa inhibitors
US6218382B1 (en) Selective factor Xa inhibitors
WO1998016524A1 (fr) DERIVES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE FACTEUR Xa
AU753842B2 (en) Selective factor Xa inhibitors
AU720513C (en) Selective factor Xa inhibitors
MXPA00001443A (en) SELECTIVE FACTOR Xa INHIBITORS
EP0939758A1 (fr) DERIVES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE FACTEUR Xa
AU8826998A (en) Selective factor xa inhibitors containing a fused azepinone structure
AU9713401A (en) Heterocyclic derivatives as factor Xa inhibitors

Legal Events

Date Code Title Description
FZDE Dead